HHS May Revamp Reimbursement Policies For Critical Medicines

The Biden administration has asked HHS to study whether new reimbursement policies could be used to shore up domestic supplies of critical medicines, including the possibility of new federal payment policies that hike profit margins for certain generic sterile injectables and cancer drugs, procurement guarantees and flexible acquisition policies. Overhauling reimbursement is one of several ways the administration is looking to secure the domestic pharmaceutical supply chain, according to a new White House report authored by HHS, FDA and the...